医学人文精神融入神经系统罕见病教学中的策略和方法

doi:10.16138/j.1673-6087.2025.05.15

摘要/Abstract

摘要：

神经系统罕见病诊疗难度大、患者负担重，为医学人文教育提供了重要契机。本文探讨将医学人文精神融入神经系统罕见病教学的策略与方法，旨在通过患者叙事、跨学科协作、开展伦理实践等途径，培养医学生的同理心和社会责任感，推动形成以患者为中心的医疗实践。教学中突出“患者价值至上”的理念，结合真实临床案例与卫生政策分析，引导学生关注疾病背后的个体困境，深化对生命尊严的理解，同时激发其致力于科研创新的内在动力。通过人文与专业的融合，提升医学教育的深度与温度，为构建更具关怀性的罕见病诊疗体系提供支持。

关键词: 神经系统罕见病, 医学人文, 人文关怀, 多发性硬化, 视神经脊髓炎

Abstract:

The diagnosis and treatment of rare neurological diseases are challenging and impose heavy burdens on patients, thus providing an important opportunity for medical humanities education. This paper explores strategies and methods for integrating medical humanistic spirit into the teaching of rare neurological diseases, aiming to cultivate medical students’ empathy and social responsibility through patient narratives, interdisciplinary collaboration, and ethical practices, thereby promoting patient-centered medical care. The teaching emphasizes the principle of “patient value first”, and guide students to understand the individual dilemmas behind diseases through real clinical cases and health policy analysis, deepen their appreciation for life dignity, and inspire motivation to commit to scientific research and innovation. By integrating humanities and professional expertise, we can enhance the compassion and depth of medical education, providing support for the development of a more compassionate rare disease healthcare system.

Key words: Rare neurological diseases, Medical humanities, Humanistic care, Multiple sclerosis, Neuromyelitis optica

中图分类号:

姚小英, 支楠, 曹雯炜, 潘元美, 戴若莲, 卢钟娇, 王刚. 医学人文精神融入神经系统罕见病教学中的策略和方法[J]. 内科理论与实践, 2025, 20(05): 426-430.

YAO Xiaoying, ZHI Nan, CAO Wenwei, PAN Yuanmei, DAI Ruolian, LU Zhongjiao, WANG Gang. Strategies and methods for integrating medical humanistic spirit into teaching of rare neurological diseases[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(05): 426-430.

参考文献 38

[1]	卫华, 李存江. 挑战神经系统罕见病[J]. 北京医学, 2019, 41(5): 339. doi: 10.3969/j.issn.1674-4721.2023.21.002
	Wei H, Li CJ. Challenging rare neurological diseases[J]. Beijing Medical Journal, 2019, 41(5): 339. doi: 10.3969/j.issn.1674-4721.2023.21.002
[2]	常精华, 宋海, 丁若溪, 等. 中国临床医生罕见病认知度及影响因素分析: 基于唐山调研数据[J]. 中国公共卫生, 2021, 37(5): 883-886. doi: 10.11847/zgggws1128096
	Chang JH, Song H, Ding RX, et al. Cognition on rare diseases and associated factors in Chinese clinicians: a cross-sectional survey in Tangshan city[J]. Chin J Public Health, 2021, 37(5): 883-886. doi: 10.11847/zgggws1128096
[3]	刘明生, 崔丽英. 神经系统罕见病治疗进展与面临的问题[J]. 罕见病研究, 2022, 1(2): 97-100. doi: 10.12376/j.issn.2097-0501.2022.02.002
	Liu MS, Cui LY. The progression and problems in diagnosis and treatment of rare neurological diseases[J]. Journal of Rare Diseases, 2022, 1(2): 97-100. doi: 10.12376/j.issn.2097-0501.2022.02.002
[4]	张学. 加快探索罕见病用药保障的“中国模式”[J]. 中国卫生, 2023(3): 25.
	Zhang X. Accelerate efforts to explore a "Chinese model" for rare disease drug coverage[J]. Chinese Health, 2023(3): 25.
[5]	Chen R, Liu S, Han J, et al. Trends in rare disease drug development[J]. Nat Rev Drug Discov, 2024, 23(3): 168-169. doi: 10.1038/d41573-023-00177-8
[6]	张小钰, 李宛霖, 赵振博, 等. 神经系统罕见病的孤儿药治疗进展[J]. 重庆医科大学学报, 2024, 49(5): 617-620. doi: 10.13406/j.cnki.cyxb.003489
	Zhang XY, Li WL, Zhao ZB, et al. Advances in orphan drugs for the treatment of rare nervous system diseases[J]. Journal of Chongqing Medical University, 2024, 49(5): 617-620. doi: 10.13406/j.cnki.cyxb.003489
[7]	胡善联. 罕见病药物政策和药物经济学研究的特征[J]. 国际药学研究杂志, 2019, 46(9): 652-658. doi: 10.13220/j.cnki.jipr.2019.09.002
	Hu SL. Characteristics of drug policy and pharmacoeconomics study on rare diseases[J]. J Int Pharm Res, 2019, 46(9): 652-658. doi: 10.13220/j.cnki.jipr.2019.09.002
[8]	Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy[J]. JAMA Neurol, 2021, 78(7): 834-841. doi: 10.1001/jamaneurol.2021.1272
[9]	Arslan D, Inan B, Kilinc M, et al. Nusinersen for adults with spinal muscular atrophy[J]. Neurol Sci, 2023, 44(7): 2393-2400. doi: 10.1007/s10072-023-06698-9
[10]	Coelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy[J]. JAMA, 2023, 330(15): 1448-1458. doi: 10.1001/jama.2023.18688
[11]	Adams D, Polydefkis M, González-Duarte A, et al. Longterm safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12 - month results of an open-label extension study[J]. Lancet Neurol, 2021, 20(1): 49-59. doi: 10.1016/S1474-4422(20)30368-9
[12]	Lamb YN. Tafamidis: a review in transthyretin amyloid cardiomyopathy[J]. Am J Cardiovasc Drugs, 2021, 21(1): 113-121. doi: 10.1007/s40256-020-00461-7
[13]	Schiffmann R, Cox TM, Dedieu JF, et al. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial[J]. Brain, 2023, 146(2): 461-474. doi: 10.1093/brain/awac379
[14]	Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late - onset Pompe disease (COMET): a phase 3, randomised, multicentre trial[J]. Lancet Neurol, 2021, 20(12): 1012-1026. doi: 10.1016/S1474-4422(21)00241-6
[15]	Hauser SL, Zielman R, Das Gupta A, et al. Efficacy and safety of four - year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open - label extension[J]. Mult Scler, 2023, 29(11-12): 1452-1464. doi: 10.1177/13524585231195346
[16]	Nie T, Blair HA. Inebilizumab: a review in neuromyelitis optica spectrum disorder[J]. CNS Drugs, 2022, 36(10): 1133-1141. doi: 10.1007/s40263-022-00949-7
[17]	Vadlamani N, Ibrahimli S, Khan FA, et al. Efficacy and safety of tetrabenazine in reducing chorea and improving motor function in individuals with Huntington's disease: a systematic review[J]. Cureus, 2024, 16(10): e71476.
[18]	Goodman AD, Bethoux F, Brown TR, et al. Long - term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two Phase 3 clinical trials[J]. Mult Scler, 2015, 21(10): 1322-31. doi: 10.1177/1352458514563591
[19]	Chiu ATG, Li J, Chang RSK, et al. Prevalence and healthcare utilization of rare neurological diseases in Hong Kong: 2014 - 2018[J]. Eur J Neurol, 2021, 28(7): 2305-2312. doi: 10.1111/ene.14852
[20]	Wright CF, Campbell P, Eberhardt RY, et al. Genomic diagnosis of rare pediatric disease in the United Kingdom and Ireland[J]. N Engl J Med, 2023, 388(17): 1559-1571. doi: 10.1056/NEJMoa2209046
[21]	Dong D, Wang Y. Challenges of rare diseases in China[J]. Lancet, 2016, 387(10031): 1906. doi: 10.1016/S0140-6736(16)30418-4
[22]	高京, 阴佳, 孙强. 健康扶贫视角下罕见病群体的致贫困境与对策[J]. 医学与社会, 2021, 34(12): 19-23. doi: 10.13723/j.yxysh.2021.12.005
	Gao J, Yin J, Sun Q. Poverty dilemma and countermeasures of rare disease groups from the perspective of health poverty alleviation[J]. Medicine and Society, 2021, 34(12): 19-23. doi: 10.13723/j.yxysh.2021.12.005
[23]	丁锦希, 季娜, 白庚亮. 我国罕见病用药市场保障政策研究[J]. 中国医药工业杂志, 2012, 43(11): 959-965. doi: 10.16522/j.cnki.cjph.2012.11.021
	Ding JX, Ji N, Bai GL. Study of orphan drug market protection policy in China[J]. Chinese Journal of Pharmaceuticals, 2012, 43(11): 959-965. doi: 10.16522/j.cnki.cjph.2012.11.021
[24]	刘虹. 人文医学引论[J]. 医学与哲学, 2019, 40(7): 1-4. doi: 10.20037/j.issn.1671-1246.2025.10.13
	Liu H. An introduction to humanistic medicine[J]. Medicine and Philosophy, 2019, 40(7): 1-4. doi: 10.20037/j.issn.1671-1246.2025.10.13
[25]	王东红. "认知—认同—践行"三位一体的医学人文教育模式探究与实践[J]. 中国医学人文, 2024, 10(2): 23-28. doi: 10.3969/j.issn.2095-9753.2024.02.009
	Wang DH. Exploration and implementation of the trinity model of medical humanities education: cognition, identification, and practice[J]. Chinese Medical Humanities, 2024, 10(2): 23-28. doi: 10.3969/j.issn.2095-9753.2024.02.009
[26]	张潞, 曾勇. 敬畏生命——医学人文的核心与基石[J]. 中华医学教育探索杂志, 2018, 17(10): 973-977. doi: 10.3760/cma.j.issn.2095-1485.2018.10.001
	Zhang L, Zeng Y. Reverence for life: the cornerstone for medical humanity[J]. Chin J Med Edu Res, 2018, 17(10): 973-977. doi: 10.3760/cma.j.issn.2095-1485.2018.10.001
[27]	国家卫生健康委办公厅, 教育部办公厅, 国家中医药局综合司, 等. 医学人文关怀提升行动方案(2024— 2027年)[J]. 协和医学杂志, 2025, 16(2): 534-536. doi: 10.12290/xhyxzz.2025-0055
	General Office of the National Health Commission, General Office of the Ministry of Education, Comprehensive Department of the National Administration of Traditional Chinese Medicine, et al. Action plan for improving medical humanistic care (2024 -2027)[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 534-536. doi: 10.12290/xhyxzz.2025-0055
[28]	魏科, 卢芳国, 陈伶利, 等. 国家级课程思政示范课程的建设与推广——以免疫学基础与病原生物学为例[J]. 中国免疫学杂志, 2022, 38(15): 1893-1897.
	Wei K, Lu FG, Chen LL, et al. Construction and promotion of state-level ideological and political courses: taking Basic Immunology and Pathogen Biology as an example[J]. Chinese Journal of Immunology, 2022, 38(15): 1893-1897.
[29]	王黎, 毛蔚, 赵维莅. 高校临床医学专业医学生有关医学人文教学的探索[J]. 内科理论与实践, 2023, 18(4): 284-286. doi: 10.16138/j.1673-6087.2023.04.014
	Wang L, Mao W, Zhao WL. Exploration on medical humanity education for clinical medicine majors in higher education institutions[J]. J Intern Med Concepts Pract, 2023, 18(4): 284-286. doi: 10.16138/j.1673-6087.2023.04.014
[30]	杨晓霖, 崔正爱, 赵颖. 叙事医学赋能《医学人文关怀提升行动方案(2024-2027年)》的实施[J]. 广东医科大学学报, 2025, 43(1): 19-26. doi: 10.20227/j.cnki.2096-3610.2025.01.002
	Yang XL, Cui ZA, Zhao Y. Narrative medicine empower the implementation of the "action plan for improving medical humanistic care (2024 - 2027)"[J]. Journal of Guangdong Medical University, 2025, 43(1): 19-26. doi: 10.20227/j.cnki.2096-3610.2025.01.002
[31]	谭红梅, 全超. 多发性硬化疾病修正治疗进展[J]. 重庆医科大学学报, 2024, 49(5): 588-592. doi: 10.13406/j.cnki.cyxb.003485
	Tan HM, Quan C. Advances in disease-modifying therapy for multiple sclerosis[J]. Journal of Chongqing Medical University, 2024, 49(5): 588-592. doi: 10.13406/j.cnki.cyxb.003485
[32]	黄文娟, 谭红梅, 常雪纯, 等. 视神经脊髓炎谱系病维持治疗研究进展[J]. 中国临床神经科学, 2022, 30(1): 92-100.
	Huang WJ, Tan HM, Chang XC, et al. A review on maintenance treatment for neuromyelitis optica spectrum[J]. Chin J Clin Neurosci, 2022, 30(1): 92-100.
[33]	苏琳, 张庆文, 李卫, 等. 情景模拟训练为基础的多元化教学在住院医生沟通技巧培训中的探索[J]. 中国高等医学教育, 2016(2): 60-61. doi: 10.3969/j.issn.1002-1701.2016.02.030
	Su L, Zhang QW, Li W, et al. Simulation-based diverse teaching in communication skills training for residents[J]. China Higher Medical Education, 2016(2): 60-61. doi: 10.3969/j.issn.1002-1701.2016.02.030
[34]	张涵. 河北省高等医学院校叙事医学教育现状及优化策略研究[D]. 2023. 石家庄: 河北医科大学.
	Zhang H. Research on the current situation and optimisation strategies of narrative medicine education in higher medical schools in Hebei province[D]. 2023. Shijiazhuang: Hebei Medical University.
[35]	贺聚良, 林翔, 关键, 等. 案例教学法联合模拟MDT的教学模式在骨肿瘤临床教学中的应用研究[J]. 名医, 2019(12): 291.
	He JL, Lin X, Guan J, et al. Application of a teaching model integrating case - based learning and simulated MDT in clinical education of bone tumors[J]. Renowned Doctor, 2019(12): 291.
[36]	万娜, 张春艳, 王淑芹, 等. 多元化教学模式在ICU护士规范化培训中的应用[J]. 检验医学与临床, 2020, 17(12): 1778-1781. doi: 10.3969/j.issn.1672-9455.2020.12.046
	Wan N, Zhang CY, Wang SQ, et al. Application of a diversified teaching model in the standardized training for ICU nurses[J]. Lab Med Cli, 2020, 17(12): 1778-1781. doi: 10.3969/j.issn.1672-9455.2020.12.046
[37]	刘艳, 王占强, 董瀚文, 等. 在线巴林特小组对精神科住院医师沟通和共情能力的影响[J]. 中国毕业后医学教育, 2024, 8(10): 736-740. doi: 10.3969/j.issn.2096-4293.2024.10.004
	Liu Y, Wang ZQ, Dong HW, et al. Impact of online Balint groups on the standardized training of psychiatry residents in communication and empathy[J]. Chinese Journal of Graduate Medical Education, 2024, 8(10): 736-740. doi: 10.3969/j.issn.2096-4293.2024.10.004
[38]	张权. 正念减压小组工作对医护人员的介入服务研究[D]. 2021. 南京: 南京大学.
	Zhang Q. Study on interventional services of medical staff based on mindfulness stress reduction group work: take the hospital Z as an example[D]. 2021. Nanjing: Nanjing University.